#Sweden #Uppsala #Beactica Therapeutics #BEA-28 #TEAD degrader

Beactica Therapeutics Selects BEA-28 as a Preclinical Candidate

In a groundbreaking announcement, Beactica Therapeutics AB, a prominent precision medicine company based in Sweden, has proudly selected BEA-28 as its preclinical candidate in the quest to develop innovative treatments for challenging solid tumors. This cutting-edge molecule represents a first-in-class TEAD degrader aimed specifically at cancers where current treatment options have proven inadequate.

Understanding BEA-28

BEA-28 is a small molecule that functions uniquely by degrading the TEAD transcription factors, which are vital components of the Hippo-YAP/TAZ pathway. Unlike traditional therapies that merely inhibit the binding action of these proteins, BEA-28 actively removes TEAD proteins from the cellular environment. This innovative approach is particularly advantageous for cancers where the activity of this pathway is linked to tumor growth, immune evasion, and eventual resistance to existing therapies.

In preclinical studies, BEA-28 demonstrated significant tumor regression at doses that were well-tolerated, suggesting its promising potential in future clinical settings. It notably restored sensitivity to KRAS inhibitors, a vital aspect in the treatment of cancers with KRAS mutations known for their aggressive nature and poor responses to therapy.

The TEAD Program's Ambitious Goals

The selection of BEA-28 is a testament to Beactica's commitment to advancing its TEAD degrader program. Dr. Per Källblad, CEO of Beactica Therapeutics, emphasized the significance of this milestone, stating that BEA-28 has met all predefined success criteria for its development stage. The comprehensive strategy and biomarker-led approach enhance the likelihood of effectively targeting cancers that have a high unmet medical need.

As BEA-28 progresses into its candidate validation stage, critical evaluations in various areas such as non-regulatory toxicology and formulation profiling will begin. These steps are essential in ensuring that the candidate meets all necessary standards before entering clinical trials.

The Science Behind BEA-28

BEA-28, closely related to its predecessor P65-047, has been engineered using Beactica’s proprietary Eclipsor™ platform. This innovative technology facilitates the development of targeted protein degradation therapies tailored for specific cancers. In preclinical cancer cell line panels, BEA-28 has shown deep therapeutic responses, particularly in high-need situations, reversing acquired resistance to KRAS inhibitors effectively.

In vivo models have also shown the ability of BEA-28 to induce significant TEAD degradation in target tissues, leading to tumor regression in xenograft models of both mesothelioma and KRAS-mutant lung cancer when administered at tolerable, once-daily doses.

Future Implications and Clinical Development

Beactica is pursuing a biomarker-driven selection strategy that plays a crucial role in identifying the tumor types most likely to benefit from BEA-28. Planned combination strategies include utilizing checkpoint inhibitors and KRAS inhibitors in tandem with BEA-28 for those cancers most resistant to current treatments.

While BEA-28 is still investigational and has not been approved for use in any market worldwide, its promise in treating solid tumors with poor prognoses positions it as a potential game-changer in oncology. The development and eventual clinical applications of BEA-28 may offer hope for patients battling cancers long deemed unmanageable.

About Beactica Therapeutics

Founded with a mission to address significant medical needs through precision medicine, Beactica Therapeutics is advancing a robust pipeline of small molecule therapeutics. By focusing on innovative drug development like BEA-28, the company aims to provide effective solutions for complex diseases. With their expertise in the Eclipsor™ platform, they uphold their promise to deliver advanced therapeutic options that add value to both patients and shareholders.

For further inquiries, visit Beactica’s official website.